The Part D Premium Lesson For Exchanges
This article was originally published in RPM Report
Executive Summary
Outgoing CMS Principal Deputy Jon Blum called on the Part D experience in trying to discuss the challenges of lowering cost sharing for specialty tier drugs in the exchanges.
You may also be interested in...
Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start
The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.